Analgesic potential of different available commercial brands of botulinum neurotoxin-A in formalin-induced orofacial pain in mice.

Autor:	Abrahão Cunha TC; Post-Graduated Program Genetics and Biochemistry, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil., Gontijo Couto AC; Post-Graduated Program Genetics and Biochemistry, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil., Januzzi E; Post-Graduated Program Orofacial Pain, CIODONTO, Belo Horizonte, MG, Brazil.; Orofacial Pain Department, MaterDei Hospital, Belo Horizonte, MG, Brazil., Rosa Ferraz Gonçalves RT; Post-Graduated Program Orofacial Pain, CIODONTO, Belo Horizonte, MG, Brazil.; Orofacial Pain Department, MaterDei Hospital, Belo Horizonte, MG, Brazil., Silva G; Post-Graduated Program Orofacial Pain, CIODONTO, Belo Horizonte, MG, Brazil.; Orofacial Pain Department, MaterDei Hospital, Belo Horizonte, MG, Brazil., Silva CR; Post-Graduated Program Genetics and Biochemistry, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil.
Jazyk:	angličtina
Zdroj:	Toxicon: X [Toxicon X] 2021 Sep 02; Vol. 12, pp. 100083. Date of Electronic Publication: 2021 Sep 02 (Print Publication: 2021).
DOI:	10.1016/j.toxcx.2021.100083
Abstrakt:	The use of botulinum neurotoxin-A (BoNT-A) is an alternative for the management of orofacial pain disorders. Although only Botox has labeled, there are other commercial brands available for use, among them: Dysport, Botulift, Prosigne, and Xeomin. The objective of the present study was to evaluate the possible differences in the antinociceptive effect evoked by different commercially available formulations of BoNT-A in an animal model of inflammatory orofacial pain induced by formalin injection. Male C57/BL6 mice (20-25 g) were submitted to the pre-treatment with five different commercial brands of BoNT-A (Botox, Botulift, Xeomin, Dysport, or Prosigne; with doses between 0.02 and 0.2 Units of Botulinum Toxin, in 20 μL of 0.9% saline) three days prior the 2% formalin injection. All injections were made subcutaneously into the right perinasal area. After formalin injections, nociceptive behaviors like rubbing the place of injection were quantified during the neurogenic (0-5 min) and inflammatory (15-30 min) phases. The treatment using Botox, Botulift, and Xeomin were able to induce antinociceptive effects in both phases of the formalin-induced pain animal model, however, Dysport and Prosigne reduced the response in neither of them. Our data suggest that the treatment using different formulations of BoNT-A is not similar in efficacy as analgesics when evaluated in formalin-induced orofacial pain in mice. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu